Related Experiment Video
Updated: May 22, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Thiazolidinedione safety
Jacqueline Kung1, Robert R Henry
1Tufts University, Division of Endocrinology, Diabetes and Metabolism, 800 Washington St #268, Boston, MA 02111, USA. JKung@tuftsmedicalcenter.org
Expert Opinion on Drug Safety
|May 24, 2012
Summary
Thiazolidinediones (TZDs) for type 2 diabetes have significant cardiovascular side effects. Future research focuses on selective PPAR gamma modulators (SPPARγMs) for safer, targeted therapies.
Area of Science:
- Pharmacology
- Endocrinology
- Cardiovascular Medicine
Background:
- Thiazolidinediones (TZDs) emerged as promising oral therapies for type 2 diabetes.
- However, significant cardiovascular side effects have limited their clinical application.
- A critical risk-benefit analysis is needed to define their current and future role.
Purpose of the Study:
- To review literature from 2000 onwards on TZD side effects (rosiglitazone, pioglitazone).
- To analyze data quality, proposed mechanisms, and clinical significance of adverse events.
- To provide a perspective on the future of TZDs in diabetes management.
Main Methods:
- Comprehensive literature review (2000-present).
- Analysis of reported side effects for rosiglitazone and pioglitazone.
- Evaluation of data quality, mechanisms, and clinical impact.
Main Results:
- First-generation TZDs are non-specific peroxisome proliferator-activated receptor (PPAR) gamma activators.
- These TZDs are associated with a broad spectrum of adverse effects, limiting their use.
- Emerging selective PPAR gamma modulators (SPPARγMs) and dual agonists show future therapeutic potential.
Conclusions:
- Current TZDs have significant limitations due to non-specific PPAR gamma activation.
- Development of targeted SPPARγMs and dual PPAR gamma/alpha agonists is advancing.
- Future TZD-related therapies aim for improved safety and efficacy in type 2 diabetes treatment.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...